✨ Free AI Report
Verrica Pharmaceuticals Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Verrica Pharmaceuticals Inc.
Company Research

Verrica Pharmaceuticals Inc.: Business Overview, Financials & Competitive Analysis

Verrica Pharmaceuticals is a dermatology therapeutics company engaged in the development and sale of medications for the treatment of skin diseases in the United States. YCANTH (VP-102) is the first and only healthcar...

Analyst-debate audio for Verrica Pharmaceuticals Inc.

AskCyborg analysts argue the bull and bear cases for Verrica Pharmaceuticals Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Clinical validation across multiple indications, strengthened balance sheet, and demonstrated commercialization progress position...

Read the full analyst-debate transcript →
Industry Dermatology Therapeutics / Specialty Pharmaceuticals
2 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Verrica Pharmaceuticals Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Verrica Pharmaceuticals Inc. Overview

Pro stress-test →

Verrica Pharmaceuticals is a dermatology therapeutics company engaged in the development and sale of medications for the treatment of skin diseases in the United States. YCANTH (VP-102) is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States. The company is capitalizing on significant unmet medical needs with an expanding pipeline and recent international expansion.

Strategic Profile

Pro stress-test →

YCANTH is in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. The company is positioned as a focused dermatology player with blockbuster potential across multiple viral skin conditions and oncologic indications.

Competitive Landscape

Pro stress-test →

Verrica operates in the dermatology therapeutics space with minimal direct competition for YCANTH in molluscum contagiosum. The common warts market is a multibillion-dollar opportunity with no FDA-approved prescription therapies, positioning Verrica as a potential pioneer. In oncologic dermatology with VP-315, the company competes in a broader field of skin cancer treatments.

Industry Context

Verrica Pharmaceuticals Inc. operates in Dermatology Therapeutics / Specialty Pharmaceuticals.

Key facts

Headquarters: West Chester, Pennsylvania, United States · Revenue: $14.3M (Q3 2025)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Verrica Pharmaceuticals Inc..

  • Phase III trial for common warts is underway, with results expected by mid-2027.
  • EU MAA filing for molluscum could occur as early as Q4 2026 following positive EMA feedback.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
  • February 2026Launch of YCANTH for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
  • +2 moreTrack every material event for Verrica Pharmaceuticals Inc. as it happens. Explore monitoring →
Get alerted when Verrica Pharmaceuticals Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Molluscum/Warts TreatmentsOff-label and over-the-counter alternatives lacking clinical validation→Basal Cell Carcinoma TherapiesExisting surgical and systemic treatment options→

Compare Verrica Pharmaceuticals Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Verrica Pharmaceuticals Inc. operates in Dermatology Therapeutics / Specialty Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Dermatology Therapeutics / Specialty Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Verrica Pharmaceuticals Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Verrica Pharmaceuticals Inc. and its top competitor on Cyborg Score”
“What did Verrica Pharmaceuticals Inc. do this quarter?”
“Is Verrica Pharmaceuticals Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Verrica Pharmaceuticals Inc. do?+
Verrica Pharmaceuticals is a dermatology therapeutics company engaged in the development and sale of medications for the treatment of skin diseases in the United States. YCANTH (VP-102) is the first and only healthcar...
What is Verrica Pharmaceuticals Inc.'s Cyborg Score?+
Verrica Pharmaceuticals Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Verrica Pharmaceuticals Inc.'s main competitors?+
Named competitors include Molluscum/Warts Treatments, Basal Cell Carcinoma Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Verrica Pharmaceuticals Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Verrica Pharmaceuticals Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Verrica Pharmaceuticals Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.